Anticoagulants and Antithrombotics

Justyna Domienik-Karlowicz, Yuri Lopatin


No abstract


Heart Failure; Anticoagulants; Antithrombotics


Bettari, L., et al., Thromboembolism and antithrombotic therapy in patients with heart failure in sinus rhythm: current status and future directions. Circ Heart Fail, 2011. 4(3): p. 361-8.

Beemath A, Stein PD, Skaf E, Al Sibae MR, et al. Risk of venous thromboembolism in patients hospitalized with heart failure. Am J Cardiol. 2006; 98 (6): 793–795.

Mebazaa A, et al. Predicting the risk of venous thromboembolism in patients hospitalized with heart failure. Circulation. 2014; 130(5): 410-418.

Al-Khadra AS, et al. Antiplatelet agents and survival: a cohort analysis from the Studies of Left Ventricular Dysfunction (SOLVD) trial. J Am Coll Cardiol, 1998; 31(2): 419-425.

Tang, L., et al., Heart failure and risk of venous thromboembolism: a systematic review and meta-analysis. Lancet Haematol, 2016. 3(1): p. e30-44.

Kannel, W.B., P.A. Wolf, and J. Verter, Manifestations of coronary disease predisposing to stroke. The Framingham study. JAMA, 1983. 250(21): p. 2942-6.

Witt, B. et al., The incidence of ischemic stroke in chronic heart failure. JCF 2007.13:489.

Alberts, V.P., et al., Heart failure and the risk of stroke: the Rotterdam Study. Eur J Epidemiol, 2010. 25(11): p. 807-12.

McCarthy, C.P., et al., Left Ventricular Thrombus After Acute Myocardial Infarction: Screening, Prevention, and Treatment. JAMA Cardiol, 2018. 3(7): p. 642-649.

Abdul-Rahim, A.H., et al., Risk of Stroke in Chronic Heart Failure Patients Without Atrial Fibrillation: Analysis of the GISSI-HF Trials. Circ, 2015. 131:1486-94.

Melgaard, L., et al., Assessment of the CHA2DS2-VASc Score in Predicting Ischemic Stroke, Thromboembolism, and Death in Patients With Heart Failure With and Without Atrial Fibrillation. JAMA, 2015. 314(10): p. 1030-8.

Ponikowski P, et al. 2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure. Eur Heart J. 2016; 37(27): 2129-2200.

Homma, S., et al., Warfarin and aspirin in patients with heart failure and sinus rhythm. N Engl J Med, 2012. 366(20): p. 1859-69.

Mega, J.L., et al., Rivaroxaban in patients with a recent acute coronary syndrome. N Engl J Med, 2012. 366(1): p. 9-19.

Connolly, S.J., Eikelboom JW, Bosch J, et al., Rivaroxaban with or without aspirin in patients with stable coronary artery disease. Lancet, 2017.39:205-218.

Zannad, F., et al., Rivaroxaban in Patients with Heart Failure, Sinus Rhythm, and Coronary Disease. N Engl J Med, 2018. Oct 4;379(14):1332-1342.

Ferreira J, Ezekowitz MD, Connolly SJ, Brueckmann M, et al. Dabigatran compared with warfarin in patients with atrial fibrillation and symptomatic heart failure: a subgroup analysis of the RE-LY trial. Eur J Heart Fail 2013; 15 (9): 1053–1061.

van Diepen S, et al. Efficacy and safety of rivaroxaban in patients with heart failure and nonvalvular atrial fibrillation: insights from ROCKET AF. Circ Heart Fail 2013;6:740–7.

McMurray JJ, Ezekowitz JA, Lewis BS, Gersh BJ, et al. Left ventricular systolic dysfunction, heart failure, and the risk of stroke and systemic embolism in patients with atrial fibrillation: insights from the ARISTOTLE trial. Circ Heart Fail 2013; 6 (3): 451–460

Magnani G, Giugliano RP, Ruff CT, Murphy SA, et al. Efficacy and safety of edoxaban compared with warfarin in patients with atrial fibrillation and heart failure: insights from ENGAGE AF-TIMI 48. Eur J Heart Fail. 2016; 18(9): 1153-1161.

Xiong, Q., et al., Non-vitamin K antagonist oral anticoagulants (NOACs) in patients with concomitant atrial fibrillation and heart failure: a systemic review and meta-analysis of randomized trials. Eur J Heart Fail, 2015. 17(11): p. 1192-1200.

Ibanez B, et al. 2017 ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation. EHJ. 2017;39: 119-177.

Leow AS, Sia CH, Tan BY, Loh JP. A meta-summary of case reports of non-vitamin K antagonist oral anticoagulant use in patients with left ventricular thrombus. J Thromb Thrombolysis. 2018; 46(1): 68-73.

Shewan LG, Coats AJS, Henein MY. Authors’ Responsibilities and Ethical Publishing. International Cardiovascular Forum Journal 2018;13:3-4, DOI: 10.17987/icfj.v13i0.525


Copyright (c) 2019 The author(s)

Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 International License.